数十亿打水漂，安进退货自免 FIC 单抗

药研界面02-02

近日，在支付了 4 亿美元首付款后，安进终止了与协和麒麟就Rocatinlimab 达成的合作。来源：协和麒麟官网Rocatinlimab 是一款OX40 单抗，基于协和麒麟专有的 POTELLIGENT 技术开发，降低了抗体糖链结构中的岩藻糖成分，进而增强了其抗体依赖性细胞毒性作用（ADCC）。该产品被开发用于特应性皮炎、哮喘、结节性痒疹等疾病。2021 年 6 月，安进引进了...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2608789416?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-02 17:10","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2608789416","market":"us","top_or_hot":-1,"title":"数十亿打水漂，安进退货自免 FIC 单抗","media":"药研界面","content":"<div>\n<p>近日，在支付了 4 亿美元首付款后，安进终止了与协和麒麟就Rocatinlimab 达成的合作。来源：协和麒麟官网Rocatinlimab 是一款OX40 单抗，基于协和麒麟专有的 POTELLIGENT 技术开发，降低了抗体糖链结构中的岩藻糖成分，进而增强了其抗体依赖性细胞毒性作用（ADCC）。该产品被开发用于特应性皮炎、哮喘、结节性痒疹等疾病。2021 年 6 月，安进引进了...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202175112a6c9d457&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>数十亿打水漂，安进退货自免 FIC 单抗</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n数十亿打水漂，安进退货自免 FIC 单抗\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-02 17:10 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202175112a6c9d457&s=b><strong>药研界面</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近日，在支付了 4 亿美元首付款后，安进终止了与协和麒麟就Rocatinlimab 达成的合作。来源：协和麒麟官网Rocatinlimab 是一款OX40 单抗，基于协和麒麟专有的 POTELLIGENT 技术开发，降低了抗体糖链结构中的岩藻糖成分，进而增强了其抗体依赖性细胞毒性作用（ADCC）。该产品被开发用于特应性皮炎、哮喘、结节性痒疹等疾病。2021 年 6 月，安进引进了...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202175112a6c9d457&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202175112a6c9d457&s=b","article_id":"2608789416","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202175112a6c9d457&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2608789416","pubTimestamp":1770023451,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近日，在支付了 4 亿美元首付款后，安进终止了与协和麒麟就Rocatinlimab 达成的合作。根据 Insight 数据库，Rocatinlimab 共启动了9 项 III 期临床，其中 8 项的适应症都为特应性皮炎。2025 年11 月，《The Lancet》杂志发表了该产品用于中重度特应性皮炎的两项III 期ROCKET-IGNITE 和 ROCKET-HORIZON 研究结果。这两项研究共纳入近 1500 名受试者。安全性方面，Rocatinlimab 组与安慰剂组治疗期间不良事件发生率总体相近，前者最常见的不良事件包括发热、寒战和口腔溃疡。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4581":"高盛持仓","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4599":"减肥药","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0122379950.USD":"贝莱德世界健康科学A2","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0058720904.USD":"联博国际健康护理基金A","BK4566":"资本集团","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","AMGN":"安进","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4588":"碎股","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC"},"translate_title":"Billions in waste, Amgen returns self-immune FIC monoclonal antibody","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1.5},"content_text":"近日，在支付了 4 亿美元首付款后，安进终止了与协和麒麟就Rocatinlimab 达成的合作。来源：协和麒麟官网Rocatinlimab 是一款OX40 单抗，基于协和麒麟专有的 POTELLIGENT 技术开发，降低了抗体糖链结构中的岩藻糖成分，进而增强了其抗体依赖性细胞毒性作用（ADCC）。该产品被开发用于特应性皮炎、哮喘、结节性痒疹等疾病。2021 年 6 月，安进引进了Rocatinlimab除日本外全球所有市场的开发、生产和商业化权益，总金额为 12.5 亿美元，其中包括4 亿美元首付款和 8.5 亿美元的里程碑付款。根据 Insight 数据库，Rocatinlimab 共启动了9 项 III 期临床，其中 8 项的适应症都为特应性皮炎。2025 年11 月，《The Lancet》杂志发表了该产品用于中重度特应性皮炎的两项III 期ROCKET-IGNITE 和 ROCKET-HORIZON 研究结果。这两项研究共纳入近 1500 名受试者。结果显示，ROCKET-IGNITE 和 ROCKET-HORIZON 研究达到了 EASI-75 与 vIGA-AD 0/1 的共同主要终点和其他关键次要终点。IGNITE 研究中，Rocatinlimab 300mg、150mg 与安慰剂组的 EASI-75 应答率分别为42%、36% 和 13%，与安慰剂的差值分别为 29.5% 与 23.4%（P<0.001）；HORIZON 研究中，Rocatinlimab300mg与安慰剂分别为33%、14%，差值 19.1%（P<0.001）。vIGA-AD 0/1 应答方面，IGNITE 研究中，Rocatinlimab 300mg、150mg 与安慰剂组分别为24%、19% 和 9%；HORIZON 研究中，Rocatinlimab300mg与安慰剂组分别为19%、7%，均具有统计学意义。安全性方面，Rocatinlimab 组与安慰剂组治疗期间不良事件发生率总体相近，前者最常见的不良事件包括发热、寒战和口腔溃疡。转自：insight数据库，版权属于原作者，仅用作信息交流分享，不作为其他推荐，如有侵权联系小编删除。会议预告4月9-10日即将在苏州举办新一届年度盛会：2026小分子药物创新开发大会，围绕7大主题：小分子研发前沿与BD出海、创新机制疗法与靶点发现、CMC与质量控制、不可成药靶点PROTAC、分子胶、合成致死靶点、AI与高通量筛选分子设计、CNS、代谢/抗病毒疾病领域等专题","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608789416","isCrawlerRequest":true}